Your browser doesn't support javascript.
loading
The Economic Burden of Atherosclerotic Cardiovascular Disease in Italy.
Mennini, Francesco S; Scortichini, Matteo; Colivicchi, Furio; Maggioni, Aldo P; Sciattella, Paolo.
Afiliação
  • Mennini FS; Faculty of Economics, Centre for Economics and International Studies, Economic Evaluation and Health Technology Assessment, University of Rome "Tor Vergata", Via Columbia, 2, 00133, Rome, Italy.
  • Scortichini M; Faculty of Economics, Centre for Economics and International Studies, Economic Evaluation and Health Technology Assessment, University of Rome "Tor Vergata", Via Columbia, 2, 00133, Rome, Italy.
  • Colivicchi F; Division of Cardiology, San Filippo Neri Hospital, Rome, Italy.
  • Maggioni AP; ANMCO Research Center-Heart Care Foundation, Florence, Italy.
  • Sciattella P; Faculty of Economics, Centre for Economics and International Studies, Economic Evaluation and Health Technology Assessment, University of Rome "Tor Vergata", Via Columbia, 2, 00133, Rome, Italy. paolo.sciattella@uniroma2.it.
Clin Drug Investig ; 2024 Sep 09.
Article em En | MEDLINE | ID: mdl-39249736
ABSTRACT

BACKGROUND:

Atherosclerotic cardiovascular diseases remain the primary cause of mortality in Italy. Individuals with a history of acute coronary syndrome, peripheral arterial disease, and ischemic stroke/transient ischemic attack face an elevated risk of recurrent major adverse cardiovascular events, including mortality. The population aging, coupled with increasing risk factors such as diabetes mellitus and obesity, exacerbates the disease's economic impact.

OBJECTIVES:

This study aims to comprehensively assess the economic burden of atherosclerotic cardiovascular diseases in Italy, specifically focusing on direct healthcare costs.

METHODS:

We analyzed real-world data from administrative databases in the Marche region and Local Health Unit Umbria 2. The economic burden of patients discharged with acute coronary syndrome, peripheral arterial disease, and ischemic stroke/transient ischemic attack was evaluated, with a focus on direct costs associated with hospitalizations, drugs, and outpatient visits. Results were stratified by age, sex, comorbidities at baseline, and adherence to lipid-lowering therapy and antihypertensive agents.

RESULTS:

Annually, nearly 350,000 patients were hospitalized for peripheral arterial disease, acute coronary syndrome, or ischemic stroke/transient ischemic attack. Direct health costs averaged €7190 per patient over a 2-year follow-up, with hospitalizations accounting for nearly 70% of the total. Male patients incurred significantly higher costs (€7467) than female patients (€6625). Costs correlated positively with age and with the number of baseline comorbidities, with a range from €5259 (0-1 comorbidities) to €17,095 (4+ comorbidities). Costs were significantly lower in adherent subjects (€6813) compared with non-adherent subjects (€7757).

CONCLUSIONS:

This study provides valuable insights into the economic implications of atherosclerotic cardiovascular diseases in Italy, emphasizing the necessity of a comprehensive approach to preventive measures, optimal medication adherence, and lifestyle modifications to mitigate its impact.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article